Actively Recruiting
Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors
Led by Loyola University · Updated on 2025-03-19
100
Participants Needed
1
Research Sites
565 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. The main objectives are: To estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate malignant and benign renal tumors. To estimate and compare the diagnostic accuracy of renal mass biopsy, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate oncocytoma from chromophobe RCC. Participants will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. These can be done on paper, electronically, or by telephone.
CONDITIONS
Official Title
Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with a clinically localized renal tumor 7 cm or smaller with a solid component suspicious for cancer based on imaging
- Have CT images of the tumor with and without contrast within the past year or planned CT scan
- At least 18 years old
- Eligible or planned for partial or radical nephrectomy as decided by primary urologist
- Eligible or planned for renal mass biopsy as decided by primary urologist
- Estimated kidney function (glomerular filtration rate) of 30 ml/min/1.73 m2 or higher
You will not qualify if you...
- Pregnant as determined by local radiology policy
- Evidence of cancer spread to lymph nodes or distant sites
- History of other cancers with concern for kidney metastasis
- Known allergy to technetium or sestamibi
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Loyola University Medical Center
Maywood, Illinois, United States, 60153
Actively Recruiting
Research Team
G
Gopal N Gupta, MD
CONTACT
A
Agnes Natonton
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here